Co-organized by the Swiss 3RCC and the FC3R, this half-day workshop aims to deliver cutting-edge insights into replacement methods in oncology research. Experts will present how in vitro and in silico approaches enable the development of models for cancer study, enhance understanding, and aid in the discovery of new therapies for cancer treatment.
Register by clicking here.
Accreditation for 0.5 day of continuing education (confirmed)
_____________________
Confirmed speakers:
Opening
Dr Marianna Kruithof-de Julio, Department for BioMedical Research, University of Bern: The progression of methods in cancer research
Developing models for cancer study
Dr Catherine Monnot, Centre de Recherche des Cordeliers, Paris: Deciphering the architectural and functional features of the renal carcinoma vasculature: Relevancy of the vascularized microtumors in 3D co-culture
Dr Olivier Preynat-Seauve, Department of Medicine, University of Geneva: The AirLiwell technology to produce standardized organoids in air/liquid interface conditions
Dr Laurent Gros, Institut de Recherche en Cancérologie, Montpellier: Development of heterotypic 3D spheroid models to study the impact of therapeutic combination on immune infiltration in pancreatic tumors
Targeting therapies for cancer treatment
Dr Muriel Cuendet, School of pharmaceutical sciences, University of Geneva: Use of 3D co-culture spheroids as a model to search for antiproliferative compounds against multiple myeloma
Dr Annabelle Ballesta, Institut Curie, Paris: Systems pharmacology to identify therapeutic targets and personalize drug combinations
Dr George Ramzy, Department of cell physiology and metabolism, University of Geneva: New approach methodologies for personalized colorectal cancer treatment
Alicia Pliego Mendieta, Laboratory for Systems Pathology and Functional Tumor Pathology, University of Zurich: AI-Predict: Artificial intelligence-mediated drug synergy prediction and validation strategy in patient-derived tumor organoid models